| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | Fortune (Associated Press) |
| URL | fortune.com/2026/07/16/testosterone-access-fda-trump-policy-shift (opens in a new tab) |
Specific Claim Evaluated
A 2023 FDA-mandated trial found no difference in heart attack, stroke and related events between testosterone and placebo, NIH studies found improvements in sexual function and a small effect on mood, and the FDA has proposed revising the label to address age-related symptoms.
Primary Research Supporting or Contradicting the Claim
TRAVERSE found testosterone noninferior to placebo for major adverse cardiac events in men aged 45 to 80 years with hypogonadism and cardiovascular risk, with more atrial fibrillation, acute kidney injury and pulmonary embolism (Lincoff et al., 2023). The Testosterone Trials found a moderate benefit for sexual function, a small benefit for mood and no benefit for vitality (Snyder et al., 2016). The FDA requested labeling updates in June 2026 (U.S. Food and Drug Administration, 2026b).
Corrected Evidence-Based Interpretation
The report is correct. The noninferiority result applies to men with confirmed hypogonadism; it does not establish cardiovascular safety in men with normal testosterone, and the requested label revisions were not final at the time of publication.
Rationale for Grade
The article reports the trial results with appropriate limits, states that the all-purpose vitality claims are not supported and describes the regulatory action as a proposal. The headline's phrase 'medically necessary' simplifies the cited finding, which was that only 12% of prescriptions met full guideline testing criteria, but the body reports the finding correctly. No statement in the body conflicts with the primary research or the regulatory record.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PMID
Supporting excerpt: "had a moderate benefit with respect to sexual function" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"